# A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Source: https://onco.cc/trials/nct05883956/  
OnCo record `nct05883956` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Azacitidine and Decitabine in myelodysplastic syndromes / neoplasms, run by Otsuka Australia Pharmaceutical Pty Ltd, active and no longer recruiting.

## Summary

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia is a phase 3 interventional study registered as NCT05883956 by Otsuka Australia Pharmaceutical Pty Ltd, with 13 participants enrolled, started 2023-12-20 and due to reach its primary completion in 2024-12-06. Interventions recorded: Subcutaneous azacitidine and Oral decitabine/cedazuridine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05883956
- Phase: 3
- Setting: A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Sponsor: Otsuka Australia Pharmaceutical Pty Ltd
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT05883956: https://clinicaltrials.gov/study/NCT05883956

## Connected records

- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Decitabine](https://onco.cc/drugs/decitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct05883956.json